About Portola Pharma
Portola Pharma is a company based in San Francisco (United States) founded in 2003 was acquired by Alexion in May 2020.. Portola Pharma has raised $296.09 million across 14 funding rounds from investors including Goldman Sachs, Alexion and D. E. Shaw Group. Portola Pharma operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter San Francisco, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$296.09 M (USD)
in 14 rounds
-
Latest Funding Round
$53.59 M (USD), Post-IPO
Jun 17, 2019
-
Investors
Goldman Sachs
& 22 more
-
Employee Count
Employee Count
-
Acquired by
Alexion
(May 05, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Leadership Team
54 people
Human Resources and Administration
25 people
Sales and Marketing
18 people
Finance and Accounting
16 people
Software Development Team
11 people
Product Management Team
10 people
Regional Team
9 people
Head Team
6 people
Unlock access to complete
Funding Insights of Portola Pharma
Portola Pharma has successfully raised a total of $296.09M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $53.59 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 14
- Last Round Post-IPO — $53.6M
-
First Round
First Round
(08 Dec 2003)
- Investors Count 22
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2019 | Amount | Post-IPO - Portola Pharma | Valuation |
investors |
|
| Mar, 2019 | Amount | Debt – Conventional - Portola Pharma | Valuation |
investors |
|
| Feb, 2017 | Amount | Post-IPO - Portola Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Portola Pharma
Portola Pharma has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Goldman Sachs, Alexion and D. E. Shaw Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location | |
|
Healthcare royalty investments are focused on US and UK markets.
|
Founded Year | Domain | Location | |
|
Global private equity investments are managed by the firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Portola Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Portola Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Portola Pharma Comparisons
Competitors of Portola Pharma
Portola Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Portola Pharma
Frequently Asked Questions about Portola Pharma
When was Portola Pharma founded?
Portola Pharma was founded in 2003.
Where is Portola Pharma located?
Portola Pharma is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Portola Pharma a funded company?
Portola Pharma is a funded company, having raised a total of $296.09M across 14 funding rounds to date. The company's 1st funding round was a Post-IPO of $150M, raised on Dec 08, 2003.
What does Portola Pharma do?
Developer of therapeutics for cardiovascular and autoimmune diseases. The companys products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism. Also, include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with the acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the companys products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases, and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkins lymphoma and chronic lymphocytic leukemia.
Who are the top competitors of Portola Pharma?
Portola Pharma's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
Who are Portola Pharma's investors?
Portola Pharma has 23 investors. Key investors include Goldman Sachs, Alexion, D. E. Shaw Group, AllianceBernstein, and T. Rowe Price.